Through an m6A-dependent mechanism, METTL16 promotes the expression of BCAT1 and BCAT2, reprogramming BCAA metabolism in AML and contributing to leukemogenesis (Han et al., 2023). The gene discussed is BCAT1; the disease is acute myeloid leukemia.